Episode 214: Physicians and COIs With Andrew Foy

Episode 214: Physicians and COIs With Andrew Foy

Dr. Andrew Foy, a cardiologist at Penn State Health, returns to the show to unpack the findings of his JAMA publication exploring industry payments in medicine and their influence on clinical practice. He examines how financial relationships with the industry may shape guideline recommendations, alter quality-of-care metrics, and contribute to potentially inappropriate prescribing practices, particularly in cases of expanded indications. Together, Chadi and Dr. Foy consider critical questions about whether medical societies should face the same scrutiny as individual physicians and whether backlash against industry involvement in healthcare is disproportionate compared to other sectors.

Related Resources

N/A

Subscribe to Healthcare Unfiltered

Other Episodes You May Enjoy...

Episode 223: From Lab to Statup: Dr. Simrit Parmar on Launching Cellenkos

Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous

Read More

Episode 222: Language Matters: A Patient Perspective

Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those

Read More

Episode 221: Major Progress in Adjuvant Renal Cell Carcinoma

Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease

Read More